Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 20181011035429
The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.
Ischaemic heart disease was the principal cause of death in Malaysia in 2016, and ST-segment elevation myocardial infarction (STEMI) is noted as the deadliest clinical presentation of Acute Coronary Syndrome. At the National Heart Association of Malaysia’s 2018 Annual Scientific Meeting, Professor Dr Wan Azman Wan Ahmad shared his insights into the management of STEMI in Malaysia, highlighting the implications of the recent TREAT trial.
At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
In this issue of MIMS Cardiology Supplement, we bring you clinical updates related to combating hypercholesterolaemia, highlighting the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in lowering low-density lipoprotein-cholesterol levels.
At a cardiology conference held in Hilton Kuala Lumpur, senior consultant cardiologist Dato’ Sri Dr Azhari Rosman spoke on the importance of non–high-density lipoprotein cholesterol (non–HDL-C) and combination therapy as a novel approach in the management of atherogenic dyslipidemia (AD).
Through a cardiology webcast hosted by Pfizer, Dr Jeyamalar Rajadurai, Dr Salim Virani and Dr Pamela Morris shared their insights into the importance of primary prevention measures in reducing the burden of atherosclerotic cardiovascular disease (ASCVD).
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
Treatment with low-to-standard dose dual combination therapy of blood pressure (BP)-lowering drugs is more effective than standard-dose monotherapy and does not increase withdrawals due to adverse events, a recent study has shown.
Untreated white coat hypertension (WCH), but not treated white coat effect (WCE), may increase the risk for cardiovascular events and all-cause mortality, suggest the results of a systematic review and meta-analysis. Out-of-office blood pressure (BP) monitoring is thus important in the diagnosis and management of hypertension.
Risk factors for 1-year mortality in heart failure (HF) patients significantly differ between those with and without chronic kidney disease (CKD), especially with regard to the use of beta-blockers or diuretics at discharge, according to a study. This suggests that these patients may benefit from individualized therapies.